[en] Epidermal growth factor receptor tyrosine kinase inhibitors represent a new
treatment option for patients with advanced nonsmall cell lung cancer (NSCLC). This
retrospective study examined to what extent previous clinical trial experience matches largescale
Western community implementation of this treatment.
In the Belgian expanded access programme, the data from 513 patients with advanced or
metastatic NSCLC, not suitable for further chemotherapy and receiving oral gefitinib 250 mg?day-1
until disease progression, death or unacceptable toxicity, were analysed.
The median (range) duration of gefitinib treatment was 2.3 months (0.0–32.7). Its use was
predominantly in second- or third-line treatment. The overall response and disease control rates
were 8.9 and 41.2%, respectively. In univariate analysis, response was more common in females
and never-smokers. In multivariate analysis, female sex was the only significant predictive factor
(odds ratio (OR) (95% confidence interval (CI)) 0.329 (0.129–0.839)). Symptom improvement was
reported in 108 patients of whom 32 (29.6%) had an objective response, 66 (61.1%) experienced
disease stabilisation and 10 (9.3%) progressed. Gefitinib was well tolerated; only 7.8% of the
patients reported grade 3 or 4 toxicity. The overall median survival was 4.7 months, with a 1-yr
survival rate of 21%. Survival was strongly influenced by a better performance status (PS) (good
PS: hazard ratio (HR) (95%CI) 0.110 (0.077–0.157)) and adenocarcinoma with bronchioloalveolar
carcinoma features histology (HR (95%CI) 0.483 (0.279–0.834)).
In conclusion, the activity of gefitinib was confirmed in the present large Western community
implementation study. Response, present in a small subgroup, led to a rewarding survival and
could be predicted by sex only. Baseline performance status and adenocarcinoma with
bronchioloalveolar carcinoma features histology were significant factors for survival.
Disciplines :
Hematology Cardiovascular & respiratory systems Oncology
Author, co-author :
van Puijenbroek, R.
Bosquee, Léon ; Centre Hospitalier Universitaire de Liège - CHU > Pneumologie-Allergologie
Meert, A. P.
Schallier, D.
Goeminne, J. C.
Tits, G.
Collard, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > HOSPITALISATION - S.I. CORONAIRES (SI -2D)
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 4: CDO02140.
Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003; 39: 55-61.
Demetri GD, Von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2005; 347: 472-480.
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237-2246.
Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290: 2149-2158.
Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 1). J Clin Oncol 2004; 22: 777-784.
Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial (INTACT 2). J Clin Oncol 2004; 22: 785-794.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000; 92: 205-216.
Haringhuizen A, Van Tinteren H, Vaessen HF, Baas P, Van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004; 15: 786-792.
Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 1103-1109.
Konishi J, Yamazaki K, Kinoshita I, et al. Analysis of the response and toxicity to gefitinib of non-small cell lung cancer. Anticancer Res 2005; 25: 435-441.
Lim ST, Wong EH, Chuah KL, et al. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. Br J Cancer 2005; 93: 23-28.
Veronese ML, Algazy K, Bearn L, et al. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. Cancer Invest 2005; 23: 296-302.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004; 10: 4383-4388.
Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small cell lung cancer (NSCLC). Br J Cancer 2004; 90: 82-86.
Miller VA, Hirsch FR, Johnson DH. Systemic therapy of advanced bronchioloalveolar cell carcinoma: challenges and opportunities. J Clin Oncol 2005; 23: 3288-3293.
Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ("Iressa", ZD1839) in non-small-cell lung cancer. Br J Cancer 2004; 91: 208-212.
Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ("Tressa", ZD1839) monotherapy for pretreated advanced non-small cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 2003; 44: 170A.
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655.
Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003; 361: 137-139.
